Cell & Gene Therapies (CGT) offer potentially curative treatment to patients with chronic and hereditary conditions but carry high price tags. One proposal to overcome such financing challenges is to create a national risk pool.
Legislative Update: HHS Secretary Kennedy Testifies Before the Senate Finance Committee on the President’s 2026 Health Care Agenda
On August 28, Chairman Crapo announced that Secretary Kennedy would testify before the Senate Finance Committee to preview the Trump administration’s 2026 health care agenda, including the Make America Healthy Again (MAHA) initiative.
This was Secretary Kennedy’s first Congressional hearing since the passage of H.R. 1 on July 4. The bill introduced sweeping changes to Medicaid and the individual marketplace, most notably Medicaid community engagement requirements and restrictions on state financing mechanisms like provider taxes. You can read more about H.R. 1 on AMCP’s resource page.
Related
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to Medicare Drug Price Negotiation Program: Draft Guidance, Manufacturer Effectuation of the Maximum Fair Price in 2028 (Draft Guidance). CMS issued this draft guidance to describe the processes and requirements for manufacturer effectuation of the maximum fair price (MFP) in 2028 for selected drugs payable under Medicare Part B and/or covered under Medicare Part D.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) for the opportunity to provide comments in response to the Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (RFI).
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
